LUCD News and Press, Lucid Diagnostics Inc. From 10/15/25

Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit PR Newswire NEW YORK , Oct. 15, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD)  ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and s...

2025-09-29 04:57:20 ET ... Read the full article on Seeking Alpha For further details see: Lucid Diagnostics: Holding Onto Medicare Coverage Hopes

Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors PR Newswire Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK , Sept. 25, 2025 /PRN...

Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs PR Newswire Scelfo to strengthen and scale Lucid's market...

2025-09-10 08:29:57 ET More on Lucid Diagnostics Lucid Diagnostics Inc. (LUCD) Investor Conference Call (Transcript) Lucid Diagnostics Inc. (LUCD) Q2 2025 Earnings Call Transcript Lucid Diagnostics announces proposed public offering of common stock Lucid near...

2025-09-08 16:31:19 ET Lucid Diagnostics Inc. (LUCD) Investor Conference Call Company Participants Matthew Riley - Director of Investor Relations Lishan Aklog - Chairman & CEO Dennis McGrath - Chief Financial Officer ... Read the full article on Seeking...

Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025 PR Newswire Conference call scheduled for Monday, September 8 , at 8:30 AM ET to discuss September 4 MolDX Contractor Advisory Committee (CAC) meeting NEW YORK , Sept. 5, 2025 ...

Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025 PR Newswire Fireside chat with Chairman & CEO Lishan Aklog , M.D., scheduled for Friday, September 5 , at 8:35 AM EDT NEW YORK , Aug. 27, 2025 /PRNewswire/ --...

PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology PR Newswire Newly-formed PAVmed subsidiary to license endoscopic imaging technology designed to identify and facilitate ablative treatment of esophageal dysplasia Lucid Dia...

PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results PR Newswire Lucid processed 2,756 EsoGuard ® 2Q25 tests, recognized revenue of $1.2 million , and secured CAC meeting on Medicare LCD for EsoGuard to be held on September 4 ...